» Articles » PMID: 22870270

Identification of Fibrin Clot-bound Plasma Proteins

Overview
Journal PLoS One
Date 2012 Aug 8
PMID 22870270
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Several proteins are known to bind to a fibrin network and to change clot properties or function. In this study we aimed to get an overview of fibrin clot-bound plasma proteins. A plasma clot was formed by adding thrombin, CaCl(2) and aprotinin to citrated platelet-poor plasma and unbound proteins were washed away with Tris-buffered saline. Non-covalently bound proteins were extracted, separated with 2D gel electrophoresis and visualized with Sypro Ruby. Excised protein spots were analyzed with mass spectrometry. The identity of the proteins was verified by checking the mass of the protein, and, if necessary, by Western blot analysis. Next to established fibrin-binding proteins we identified several novel fibrin clot-bound plasma proteins, including α(2)-macroglobulin, carboxypeptidase N, α(1)-antitrypsin, haptoglobin, serum amyloid P, and the apolipoproteins A-I, E, J, and A-IV. The latter six proteins are associated with high-density lipoprotein particles. In addition we showed that high-density lipoprotein associated proteins were also present in fibrinogen preparations purified from plasma. Most plasma proteins in a fibrin clot can be classified into three groups according to either blood coagulation, protease inhibition or high-density lipoprotein metabolism. The presence of high-density lipoprotein in clots might point to a role in hemostasis.

Citing Articles

Mechanisms influencing the high prevalence of COVID-19 in diabetics: A systematic review.

Jain R, Mathew D Med Res Arch. 2024; 11(10).

PMID: 38933091 PMC: 11198970. DOI: 10.18103/mra.v11i10.4540.


Agnostic identification of plasma biomarkers for postpartum hemorrhage risk.

Reitsma S, Barsoum J, Hansen K, Sassin A, Dzieciatkowska M, James A Am J Obstet Gynecol. 2024; 232(2):220.e1-220.e18.

PMID: 38710264 PMC: 11538378. DOI: 10.1016/j.ajog.2024.04.050.


Comprehensive Analysis of the Role of Fibrinogen and Thrombin in Clot Formation and Structure for Plasma and Purified Fibrinogen.

Risman R, Belcher H, Ramanujam R, Weisel J, Hudson N, Tutwiler V Biomolecules. 2024; 14(2).

PMID: 38397467 PMC: 10886591. DOI: 10.3390/biom14020230.


The hepatokine FGL1 regulates hepcidin and iron metabolism during anemia in mice by antagonizing BMP signaling.

Sardo U, Perrier P, Cormier K, Sotin M, Personnaz J, Medjbeur T Blood. 2024; 143(13):1282-1292.

PMID: 38232308 PMC: 11103088. DOI: 10.1182/blood.2023022724.


Proteomics-Based Approach to Identify Novel Blood Biomarker Candidates for Differentiating Intracerebral Hemorrhage From Ischemic Stroke-A Pilot Study.

Malicek D, Wittig I, Luger S, Foerch C Front Neurol. 2022; 12:713124.

PMID: 34975707 PMC: 8719589. DOI: 10.3389/fneur.2021.713124.


References
1.
Holst A, Jensen G, Prescott E . Risk factors for venous thromboembolism: results from the Copenhagen City Heart Study. Circulation. 2010; 121(17):1896-903. DOI: 10.1161/CIRCULATIONAHA.109.921460. View

2.
Valnickova Z, Enghild J . Human procarboxypeptidase U, or thrombin-activable fibrinolysis inhibitor, is a substrate for transglutaminases. Evidence for transglutaminase-catalyzed cross-linking to fibrin. J Biol Chem. 1998; 273(42):27220-4. DOI: 10.1074/jbc.273.42.27220. View

3.
Potempa J, Korzus E, Travis J . The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J Biol Chem. 1994; 269(23):15957-60. View

4.
Reiner A, Siscovick D, Rosendaal F . Hemostatic risk factors and arterial thrombotic disease. Thromb Haemost. 2001; 85(4):584-95. View

5.
Koopman J, Haverkate F, Lord S, Grimbergen J, Mannucci P . Molecular basis of fibrinogen Naples associated with defective thrombin binding and thrombophilia. Homozygous substitution of B beta 68 Ala----Thr. J Clin Invest. 1992; 90(1):238-44. PMC: 443086. DOI: 10.1172/JCI115841. View